WO1999002676A3 - Mutants of gef proteins - Google Patents
Mutants of gef proteins Download PDFInfo
- Publication number
- WO1999002676A3 WO1999002676A3 PCT/EP1998/004752 EP9804752W WO9902676A3 WO 1999002676 A3 WO1999002676 A3 WO 1999002676A3 EP 9804752 W EP9804752 W EP 9804752W WO 9902676 A3 WO9902676 A3 WO 9902676A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gef
- tryptophan
- mutated
- amino acid
- mutants
- Prior art date
Links
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 108040001860 guanyl-nucleotide exchange factor activity proteins Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- 101000580040 Mus musculus Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention concerns a GEF mutant in which tryptophan (W) corresponding to position 1056 of the protein called CDC25Mm is mutated to an acidic amino acid, preferably glutammic acid, or tryptophan (W) at position 1056 and serine at position 1124 are mutated into an acidic acid and valine, respectively. The invention further provides the gene sequences encoding said amino acid sequences, and their application in the treatment of proliferative disorders and in the development of assays suitable for the identification of candidate agents able to disrupt the ras/GEF complex.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU84420/98A AU8442098A (en) | 1997-07-08 | 1998-07-07 | Mutants of gef proteins |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI97A001627 | 1997-07-08 | ||
| IT97MI001627A IT1293491B1 (en) | 1997-07-08 | 1997-07-08 | MUTANTS OF GEF PROTEINS AND PLASMIDS SUITABLE FOR THEIR SYNTHESIS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1999002676A2 WO1999002676A2 (en) | 1999-01-21 |
| WO1999002676A3 true WO1999002676A3 (en) | 1999-07-08 |
Family
ID=11377527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1998/004752 WO1999002676A2 (en) | 1997-07-08 | 1998-07-07 | Mutants of gef proteins |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU8442098A (en) |
| IT (1) | IT1293491B1 (en) |
| WO (1) | WO1999002676A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315352A (en) * | 2000-03-24 | 2001-10-03 | 上海博德基因开发有限公司 | Polypeptide-human guanine intertranscription factor 10 and polynucleotide for coding it |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993021314A1 (en) * | 1992-04-21 | 1993-10-28 | Rhone-Poulenc Rorer S.A. | Peptides having a gdp exchange factor activity, nucleic acid sequences coding for said peptides, preparation and utilization |
-
1997
- 1997-07-08 IT IT97MI001627A patent/IT1293491B1/en active IP Right Grant
-
1998
- 1998-07-07 AU AU84420/98A patent/AU8442098A/en not_active Abandoned
- 1998-07-07 WO PCT/EP1998/004752 patent/WO1999002676A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993021314A1 (en) * | 1992-04-21 | 1993-10-28 | Rhone-Poulenc Rorer S.A. | Peptides having a gdp exchange factor activity, nucleic acid sequences coding for said peptides, preparation and utilization |
Non-Patent Citations (3)
| Title |
|---|
| MARTEGANI E. ET AL.: "Cloning by functional complementation of a mouse cDNA encoding a homologoue of CDC25, a Saccharomyces cerevisiae RAS activator", EMBO JOURNAL, vol. 11, no. 6, June 1992 (1992-06-01), pages 2151 - 2157, XP000611568 * |
| PARK W. ET AL.: "Amino acid residues in the CDC25 guanine nucleotide exchange factor critical for interaction with Ras", MOLECULAR AND CELLULAR BIOLOGY, vol. 14, no. 12, December 1994 (1994-12-01), pages 8117 - 8122, XP002098862 * |
| PARK W. ET AL.: "Identification of a dominant-negative mutation in the yeast CDC25 guanine nucleotide exchange factor for Ras", ONCOGENE, vol. 14, no. 7, 20 February 1997 (1997-02-20), pages 831 - 836, XP002098824 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999002676A2 (en) | 1999-01-21 |
| ITMI971627A0 (en) | 1997-07-08 |
| ITMI971627A1 (en) | 1999-01-08 |
| IT1293491B1 (en) | 1999-03-01 |
| AU8442098A (en) | 1999-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL299053A1 (en) | Amino acid compound being a nucleic acid, vector, host cell, genomic zyme clone, method of diagnozing the alzheimer disease, method of determining and expressing a nucleic acid sequence | |
| WO1999024463A3 (en) | Signal peptide-containing proteins | |
| DE69941701D1 (en) | MUTANTS OF FLT3-L AND ITS USES | |
| CA2158750A1 (en) | Monoclonal antibodies to casein kinase i polypeptides | |
| AU7652194A (en) | A method of assaying collagen fragments in body fluids, a test kit and means for carrying out the method and use of the method to diagnose the presence of disorders associated with the metabolism of collagen | |
| WO1996009386A3 (en) | Allelic variation of the serotonin 5ht2c receptor | |
| WO2000009709A3 (en) | Proteases and associated proteins | |
| IL95223A (en) | Dna sequence for production of serine protease inhibitors | |
| AU2002223044A1 (en) | Kit and method for detecting the esm-1 protein | |
| WO2001020004A3 (en) | Protein phosphatase and kinase proteins | |
| WO2000012703A3 (en) | Protein transport-associated molecules | |
| WO2001005970A3 (en) | Gtp-binding protein associated factors | |
| WO2000017355A3 (en) | Human cytoskeleton associated proteins | |
| AU2126400A (en) | Detection of small molecules by use of a piezoelectric sensor | |
| WO1999024587A3 (en) | Human phospholipase a2 protein and dna encoding it | |
| WO2000014251A3 (en) | Human transferase proteins | |
| WO1999033981A3 (en) | Human signal peptide-containing proteins | |
| WO1999002676A3 (en) | Mutants of gef proteins | |
| WO1999061614A3 (en) | Human socs proteins | |
| WO2000015770A3 (en) | Human serine/threonine protein kinases | |
| WO1999041387A3 (en) | Prostate-associated serine protease | |
| AU4908799A (en) | Determination of the hydrophobic pulmonary surfactant protein sp-c | |
| WO1998011130A3 (en) | Mammalian ependymin-like proteins | |
| WO2000001821A3 (en) | Neurotransmission associated proteins | |
| Polgar et al. | Peptic peptide of thiolsubtilisin. Analytical evidence for the chemical transformation of the essential serine-221 to cysteine-221 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1999508179 Format of ref document f/p: F |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| 122 | Ep: pct application non-entry in european phase |